Pluri (PLUR) FCF Margin % : -3,590.48% (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Pluri FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pluri's Free Cash Flow for the three months ended in Dec. 2023 was $-3.77 Mil. Pluri's Revenue for the three months ended in Dec. 2023 was $0.11 Mil. Therefore, Pluri's FCF Margin % for the quarter that ended in Dec. 2023 was -3,590.48%.

As of today, Pluri's current FCF Yield % is -62.61%.

The historical rank and industry rank for Pluri's FCF Margin % or its related term are showing as below:

PLUR' s FCF Margin % Range Over the Past 10 Years
Min: -115821.74 Med: -11886.89 Max: -712.05
Current: -5271.43

During the past 13 years, the highest FCF Margin % of Pluri was -712.05%. The lowest was -115821.74%. And the median was -11886.89%.

PLUR's FCF Margin % is ranked worse than
88.43% of 1037 companies
in the Biotechnology industry
Industry Median: -147.18 vs PLUR: -5271.43

Pluri FCF Margin % Historical Data

The historical data trend for Pluri's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri FCF Margin % Chart

Pluri Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

-54,985.19

-115,821.74

-15,718.38

-8,055.40

Pluri Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-317,400.00	-7,005.75	-2,697.30	-11,037.04	-3,590.48

Competitive Comparison of Pluri's FCF Margin %

For the Biotechnology subindustry, Pluri's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pluri's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pluri's FCF Margin % falls into.

Pluri FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pluri's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-23.119	/	0.287
	=	-8,055.40 %

Pluri's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.77	/	0.105
	=	-3,590.48 %

Pluri FCF Margin % Related Terms

Thank you for viewing the detailed overview of Pluri's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri (PLUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

Y55:Germany

Address

MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409

Website

https://www.pluri-biotech.com

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.

Executives

Lorne Kenneth Abony	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman	officer: Chief Executive Officer	63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership	10 percent owner	BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer	director	33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun	director	9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay	officer: Chief Financial Officer	ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat	director	HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram	director	24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda	officer: Chief Financial Officer	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain	director	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi	officer: Chief Financial Officer	MATAM PARK, BUILDING 05, HAIFA L3 31905